Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.12638 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Role of Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia in the Contemporary Era.
Cancers (Basel)
December 2024
Division of Hematology and Oncology, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.
The treatment of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-cell ALL) has seen substantial progress over the past two decades. The introduction of tyrosine kinase inhibitor (TKIs) has resulted in dramatic improvements in long-term survival. Allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its curative potential, has always been an integral part of the treatment algorithm of Ph+ ALL.
View Article and Find Full Text PDFA complex case of right heart masses in a leukemia patient: a case report.
J Cardiothorac Surg
January 2025
Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background: A patient with acute myeloid leukemia (AML) presented with a cardiac mass of unknown nature. This case underscores the importance of careful monitoring and a multidisciplinary approach in managing and differentiation of rare cardiac complications in leukemia patients. It aims to improve diagnostic accuracy and therapeutic outcomes in similar challenging scenarios.
View Article and Find Full Text PDFFactors affecting pretransplant muscle strength in allogeneic stem cell transplant candidates prior transplantation.
Support Care Cancer
January 2025
Department of Medical Oncology, Heidelberg University Hospital and National Center for Tumor Diseases Heidelberg, a partnership between German Cancer Research Center (DKFZ) and University Medical Center Heidelberg, Im Neuenheimer Feld 460, 69120, Heidelberg, Germany.
Purpose: Physical performance is crucial for prognosis after allogeneic hematopoietic stem cell transplantation (allo-HCT). Cardiorespiratory fitness has already been shown to have prognostic value, and there is increasing evidence that muscle strength and associated parameters (e.g.
View Article and Find Full Text PDFOutcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience.
Ann Hematol
January 2025
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, Duesseldorf, 40225, Germany.
As median age of patients with acute myeloid leukemia is 72 years, older patients continue to be a vulnerable cohort representing significant challenges in clinical practice. Patient-specific comorbidities as well as leukemia-specific unfavorable molecular- and cytogenetics confer even poorer outcomes. Treatment of AML therefore needs to be less toxic to prevent harm while lowering or eradicating leukemic burden to prolong survival.
View Article and Find Full Text PDFGene therapy for β-thalassemia: current and future options.
Trends Mol Med
January 2025
Université Paris Cité, Imagine Institute, Laboratory of chromatin and gene regulation during development, INSERM UMR 1163, 75015, Paris, France.
Beta-thalassemia is a severe, hereditary blood disorder characterized by anemia, transfusion dependence, reduced life expectancy, and poor quality of life. Allogeneic transplantation of hematopoietic stem cells (HSCs) is the only curative treatment for transfusion-dependent β-thalassemia, but a lack of compatible donors prevents the use of this approach for most patients. Over the past 20 years, the rise of gene therapy and the development of lentiviral vectors and genome-editing tools has extended curative options to a broader range of patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!